↓ Skip to main content

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Overview of attention for article published in BMC Cancer, May 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)

Mentioned by

twitter
31 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
Published in
BMC Cancer, May 2021
DOI 10.1186/s12885-021-08085-z
Pubmed ID
Authors

P. Grivas, Y. Loriot, R. Morales-Barrera, M. Y. Teo, Y. Zakharia, S. Feyerabend, N. J. Vogelzang, E. Grande, N. Adra, A. Alva, A. Necchi, A. Rodriguez-Vida, S. Gupta, D. H. Josephs, S. Srinivas, K. Wride, D. Thomas, A. Simmons, A. Loehr, R. L. Dusek, D. Nepert, S. Chowdhury

Twitter Demographics

The data shown below were collected from the profiles of 31 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 17%
Researcher 1 8%
Librarian 1 8%
Student > Postgraduate 1 8%
Student > Master 1 8%
Other 0 0%
Unknown 6 50%
Readers by discipline Count As %
Medicine and Dentistry 2 17%
Nursing and Health Professions 1 8%
Agricultural and Biological Sciences 1 8%
Arts and Humanities 1 8%
Unknown 7 58%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2021.
All research outputs
#1,357,520
of 18,838,632 outputs
Outputs from BMC Cancer
#195
of 6,831 outputs
Outputs of similar age
#35,583
of 342,349 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 18,838,632 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,831 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,349 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them